{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:17Z","timestamp":1790286917487,"version":"4.1.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Dermatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1111\/ced.13608","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T04:36:11Z","timestamp":1527741371000},"page":"890-894","source":"Crossref","is-referenced-by-count":12,"title":["Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition"],"prefix":"10.1093","volume":"43","author":[{"given":"A. K.","family":"Dewan","sequence":"first","affiliation":[{"name":"Department of Dermatology; The Center for Cutaneous Oncology; Dana-Farber Cancer Institute and Brigham and Women's Hospital; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sowerby","sequence":"additional","affiliation":[{"name":"Department of Dermatology; The Center for Cutaneous Oncology; Dana-Farber Cancer Institute and Brigham and Women's Hospital; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jadeja","sequence":"additional","affiliation":[{"name":"Department of Pathology; Brigham and Women's Hospital; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Pathology; Brigham and Women's Hospital; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology; Dana-Farber Cancer Institute; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Chronic Lymphocytic Leukemia Center and Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. R.","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"Department of Dermatology; The Center for Cutaneous Oncology; Dana-Farber Cancer Institute and Brigham and Women's Hospital; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"10.1111\/ced.13608-BIB0001|ced13608-cit-0001","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/ced.13608-BIB0002|ced13608-cit-0002","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/aps.2015.71","article-title":"PI3K isoform-selective inhibitors: next-generation targeted cancer therapies","volume":"36","author":"Wang","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1111\/ced.13608-BIB0003|ced13608-cit-0003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1111\/ced.13608-BIB0004|ced13608-cit-0004","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1111\/ced.13608-BIB0005|ced13608-cit-0005","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia","volume":"126","author":"O'Brien","year":"2015","journal-title":"Blood"},{"key":"10.1111\/ced.13608-BIB0006|ced13608-cit-0006","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/ced.13608-BIB0007|ced13608-cit-0007","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2133.1996.d01-1114.x","article-title":"Pityriasis rubra pilaris and human immunodeficiency virus infection-type 6 pityriasis rubra pilaris?","volume":"135","author":"Misery","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1111\/ced.13608-BIB0008|ced13608-cit-0008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1525-1470.1987.tb00747.x","article-title":"Childhood-onset pityriasis rubra pilaris with immunologic abnormalities","volume":"4","author":"Shvili","year":"1987","journal-title":"Pediatr Dermatol"},{"key":"10.1111\/ced.13608-BIB0009|ced13608-cit-0009","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamadermatol.2016.3601","article-title":"Pityriasis rubra pilaris type V as an autoinflammatory disease by CARD14 mutations","volume":"153","author":"Takeichi","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1111\/ced.13608-BIB0010|ced13608-cit-0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/11530070-000000000-00000","article-title":"Pityriasis rubra pilaris: a review of diagnosis and treatment","volume":"11","author":"Klein","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/ced.13608-BIB0011|ced13608-cit-0011","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Patton","year":"2006","journal-title":"J Immunol"},{"key":"10.1111\/ced.13608-BIB0012|ced13608-cit-0012","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"10.1111\/ced.13608-BIB0013|ced13608-cit-0013","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/cncr.30069","article-title":"Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity","volume":"122","author":"Thompson","year":"2016","journal-title":"Cancer"},{"key":"10.1111\/ced.13608-BIB0014|ced13608-cit-0014","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","article-title":"Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris","volume":"153","author":"Feldmeyer","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1111\/ced.13608-BIB0015|ced13608-cit-0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1684\/ejd.2011.1362","article-title":"CD4+CD25+ T-regulatory cells in psoriasis. Correlation between their numbers and biologics-induced clinical improvement","volume":"21","author":"Richetta","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1111\/ced.13608-BIB0016|ced13608-cit-0016","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis. A study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fced.13608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ced.13608\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:46:35Z","timestamp":1676385995000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/43\/8\/890\/6597668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,12]]}},"URL":"https:\/\/doi.org\/10.1111\/ced.13608","archive":["Portico"],"relation":{},"ISSN":["0307-6938"],"issn-type":[{"value":"0307-6938","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5,30]]}}}